US Stock MarketDetailed Quotes

ENGN enGene Holdings

Watchlist
  • 14.500
  • -0.020-0.14%
Trading May 9 10:58 ET
631.94MMarket Cap-8192P/E (TTM)

About enGene Holdings Company

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Company Profile

SymbolENGN
Company NameenGene Holdings
Listing DateFeb 1, 2022
Founded2023
CEOMr. Jason D. Hanson, B.S.,J.D.
MarketNASDAQ
Securities TypeOrdinary Shares
Fiscal Year Ends10-31
Address4868 Rue Levy,Suite 220
CitySaint-Laurent
ProvinceQuébec
CountryCanada
Zip CodeH4R 2P1
Phone1-514-332-4888
Websitehttp://www.engene.com

Company Executives

  • Name
  • Position
  • Salary
  • Jason D. Hanson, B.S.,J.D.
  • Director; Chief Executive Officer of Company and enGene Inc
  • 2.19M
  • Dr. James Crowley Sullivan
  • Chief Scientific Officer
  • 896.24K
  • Ryan Daws
  • Chief Financial Officer, Head of Business Development and Principal Accounting Officer
  • --
  • Dr. Richard P. Bryce
  • Chief Medical Officer of the Company and enGene USA, Inc.
  • --
  • Dr. Anthony Tzeyew Cheung
  • Chief Technology Officer
  • --
  • Dr. Alexander Julian Nichols
  • President and Chief Operating Officer of Company and enGene Inc
  • 969.95K
  • Dr. Richard M. Glickman,L.L.D.
  • Independent Director; Chairman of the Board of enGene Inc
  • --
  • Lota S. Zoth, C.P.A.
  • Director
  • --
  • Gerry Brunk
  • Independent Director
  • --
  • Dr. Jasper Bos, PhD
  • Independent Director
  • --
  • Wouter Joustra
  • Independent Director
  • --
  • Paul J. Hastings
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg